Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 2 I, 1999, Pages 425-432

  La Rosa, Mario ^a   Ranno, Carmen ^a   André, Claude ^b   Carat, Florina ^b   Tosca, Maria Angela ^c   Canonica, Giorgio Walter ^c  

^a Clinical Pediatrica I   (Italy)

^b Stallergenes SA   (France)

^c Allerg and Clin Immunology Service   (Italy)

Author keywords

Children; Parietaria; Seasonal rhinoconjunctivitis; Sublingual swallow immunotherapy

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; PARIETARIA JUDAICA EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG;

ADOLESCENT; ANAPHYLAXIS; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SUBLINGUAL DRUG ADMINISTRATION; VACCINATION;

PARIETARIA JUDAICA;

EID: 0032866139     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70388-X     Document Type: Article

References (25)

1. D'Amato G, Spieksma M, Liccardi G, Jäger S, Russo M, Kontou-Fili K, et al. Pollen-related allergy in Europe. Allergy 1998;53:567-78.
2. Kaufman HS. Parietaria: an unrecognized cause of respiratory allergy in the United States. Ann Allergy 1990;64:293-6.
3. Bass D, Baldo BA. Parietaria as a cause of asthma. Med J Aust 1984;14:511-4.
4. Malling HJ, Abreu Noqueira E, Björkstén B, Bousquet J, Caillot D, Canonica GW. WHO Position Paper, allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53(44 Suppl):20-3.
5. Purello d'Ambrosio F, Ricciardi L, Isola S, Puccinelli P, Musarra A. Rush sublingual immunotherapy in Parietaria allergic patients. Allergol Immunopathol (Madr) 1996;24:146-51.
6. Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen induced rhinitis: a double-blind study. J Invest Allergol Clin Immunol 1995;5:25-30.
7. Ariano R, Panzani RC, Augeri G. Efficacy and safety of oral immunotherapy in respiratory allergy to Parietaria judaica pollen: a double blind study. J Invest Allergol Clin Immunol 1998;8:155-60.
8. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. Arch Ophthalmol 1990;108:84-8.
9. Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998;53:461-72.
10. Brostoff J, Scadding GK. Low dose sublingual therapy in patients with allergen rhinitis due to house dust mite. Clin Allergy 1986;16:483-91.
11. Van Niekerk CH, De Wet JI. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay-fever: a double-blind study. Clin Allergy 1987;17:507-13.
12. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite: a double-blind study. Allergol Immunopathol (Madr) 1990;18:277-84.
13. Nelson HS, Oppenheimer J, Vatsia GA. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993;92:229-36.
14. Sabbah A, Hassoun S, Le Seilin J, André C, Sicard H. A double-blind placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309-13.
15. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts: a double-blind study. Allergol Immunopathol (Madr) 1995;23:224-30.
16. Casanova M, Guera F, Moreno C, Miguel R, Daza JC. Double-blind, placebo-controlled clinical trial of pre-seasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. J Invest Allergol Clin Immunol 1994;4:305-14.
17. Hirsch T, Sahn M, Eupold W. Double-blind placebo controlled study of sublingual immunotherapy with house dust mite extract in children. Pediatr Allergy Immunol 1997;8:21-7.
18. Horak E, Stübner P, Berger UE, Marks B, Toth J, Jäger S. Immunotherapy with sublingual birch pollen extract: a short-term double-blind placebo study. J Invest Allergol Clin Immunol 1998;8:165-71.
19. Passalacqua G, Albano M, Fregonese L, Riccio A, Prontato C, Mela GS, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629-32.
20. Clavel R, Bousquet J, André C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of standardized five grass-pollen extract in rhinitis. Allergy 1998;53:493-8.
21. Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, André C, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in paediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53:662-72.
22. Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients. Clin Exp Allergy 1996;26:1253-61.
23. Passalacqua G, Bagnasco M, Mariani G, Falagiani P, Canonica GW. Local immunotherapy: pharmacokinetics and efficacy. Allergy 1998;53:477-84.
24. Macatinia SE, Hosken NA, Litton M. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CDA+ T cells. J Immunol 1995;154:5071-9.
25. Passalacqua G, Canonica GW. Alternative routes for allergen-specific immunotherapy. J Invest Allergol Clin Immunol 1996;6:81-7.